Safety of low-dose radiotherapy in newly diagnosed stage I/II extranodal NK/T-cell lymphoma: a single-center retrospective analysis
Open Access
- 5 July 2025
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (7) , 3723-3731
Abstract
This study aimed to investigate the feasibility and safety of low-dose radiotherapy (RT) (< 50 Gy) in patients with stage I/II Extranodal NK/T-cell lymphoma (ENKTCL). Clinical and treatment data from 158 stage I/II ENKTCL patients who received combined chemoradiotherapy at the First Affiliated Hospital of Zhengzhou University from 2020 to 2022 were retrospectively analyzed to compare locoregional control (LC) and survival outcomes between high-dose (≥ 50 Gy) and low-dose (< 50 Gy) RT groups. All patients achieved an objective response (OR) after treatment, with a median follow-up of 51 months. The 5-year overall survival (OS) and progression-free survival (PFS) rates were 90.1% and 81.7% in the high-dose group (n = 130), compared to 84.0% and 68.2% in the low-dose group (n = 28), with no significant statistical differences between the two groups. Notably, no local recurrence was observed in the low-dose group (100% local control rate), and the incidence of grade ≥ 3 RT-related adverse events (AEs) was significantly lower in the low-dose group than in the high-dose group. Preliminary evidence suggests that for newly diagnosed stage I/II ENKTCL patients receiving combined chemoradiotherapy, low-dose radiotherapy may not compromise LC and survival outcomes while reducing the incidence of grade 3–4 adverse events, with 40–45 Gy appearing to be the optimal dose range within the examined parameters.Keywords
Funding Information
- Qingjiang Chen
This publication has 22 references indexed in Scilit:
- Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology GroupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T‐cell lymphoma: A randomized, controlled, open‐label, multicenter studyInternational Journal of Cancer, 2020
- Validation of nomogram-revised risk index and comparison with other models for extranodal nasal-type NK/T-cell lymphoma in the modern chemotherapy era: indication for prognostication and clinical decision-makingLeukemia, 2020
- Risk‐dependent curability of radiotherapy for elderly patients with early‐stage extranodal nasal‐type NK/T‐cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)Cancer Medicine, 2018
- Radiotherapy is essential after complete response to asparaginase-containing chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG)Radiotherapy and Oncology, 2018
- The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T‐cell lymphoma, nasal type, in the United StatesCancer, 2017
- Association of Improved Locoregional Control With Prolonged Survival in Early-Stage Extranodal Nasal-Type Natural Killer/T-Cell LymphomaJAMA Oncology, 2017
- Radiotherapy Alone With Curative Intent in Patients With Stage I Extranodal Nasal-Type NK/T-Cell LymphomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2012
- Failure patterns and clinical implications in early stage nasal natural killer/T‐cell lymphoma treated with primary radiotherapyCancer, 2011
- Extranodal natural killer/T‐cell lymphoma, nasal typeCancer, 2005